Cargando…
SUN-337 Anti-tumorigenic Effects Of The Maternal Leucine Zipper Kinase (MELK) Inhibitor, OTSSP167, In Pre-clinical In Vivo Models Of Adrenocortical Carcinomas (ACC)
ACC is an aggressive endocrine cancer with limited therapeutic options and poor survival rates. In patients with progressive disease, standard EDP (etoposide, doxorubicin and cisplatin) chemotherapy is associated with only a modest response and progression free survival of 5 months. Mitotane, the on...
Autores principales: | KAR, ADWITIYA, Zhang, Yu, Yacob, Beteleham, Tompkins, Kenneth, Bagby, Stacey, Leong, Stephen, Pitts, Todd, Wierman, Margaret, Kiseljak-Vassiliades, Katja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552789/ http://dx.doi.org/10.1210/js.2019-SUN-337 |
Ejemplares similares
-
OR04-6 Comprehensive Profiling of the MELK Inhibitor OTSSP167's Action and Its Effect on Sensitization to Wee1 Inhibitor AZD1775 in a Spectrum of ACC Models
por: Bagby, Stacey, et al.
Publicado: (2022) -
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease
por: Muller, Joséphine, et al.
Publicado: (2018) -
SAT-LB064 Mitotane Induces Autophagy: A Mechanism to Promote Chemoresistance in Adrenocortical Carcinoma
por: Tompkins, Kenneth, et al.
Publicado: (2019) -
OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases
por: Ji, Wenbin, et al.
Publicado: (2016) -
Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia
por: Bridges, Cory Seth, et al.
Publicado: (2022)